Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

MaxCyte, Inc. MXCT

Healthcare  —  Medical Devices
1.17 (0.02) (1.68%) as of 25 Sep
Market cap
$122.8M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

MaxCyte, Inc. (MXCT) Business Profile

Updated before January 2025

Company Overview

MaxCyte, Inc. (MXCT) is a leading biotechnology company specializing in cell engineering and therapeutic development. Founded in 1998 and headquartered in Gaithersburg, Maryland, MaxCyte has established itself as a pioneer in the field of cell-based therapies. The company was founded by Dr. Douglas Doerfler, who also serves as the President and Chief Executive Officer (CEO). Under his leadership, MaxCyte has grown into a globally recognized name in the biotechnology sector, with a strong focus on innovation and collaboration.

MaxCyte’s mission is to accelerate the discovery, development, and commercialization of next-generation cell-based therapies. The company’s proprietary technology platform, Flow Electroporation®, has been instrumental in enabling advancements in gene editing, immuno-oncology, and regenerative medicine. MaxCyte collaborates with leading pharmaceutical and biotechnology companies worldwide, leveraging its expertise to drive the development of cutting-edge therapies.

Core Business Segments

1. Proprietary Technology Platform

MaxCyte’s Flow Electroporation® technology is at the core of its business. This platform enables high-performance cell engineering by delivering molecules such as DNA, RNA, and proteins into cells with high efficiency and minimal toxicity. The technology is widely used in research and clinical applications, including gene editing, CAR-T cell therapy, and regenerative medicine.

Key Products:

  • ExPERT™ Platform: A suite of instruments and disposables designed for cell engineering. The ExPERT™ platform includes three main systems:
    • ATx™: Designed for small-scale research and development.
    • STx™: Ideal for clinical research and early-stage clinical trials.
    • GTx™: Tailored for large-scale clinical and commercial manufacturing.

2. Licensing and Partnerships

MaxCyte collaborates with pharmaceutical and biotechnology companies to advance cell-based therapies. The company licenses its technology to partners, enabling them to develop and commercialize innovative therapies. These partnerships often include milestone payments and royalties, contributing significantly to MaxCyte’s revenue.

Key Collaborations:

  • Partnerships with leading companies in gene editing, such as CRISPR Therapeutics and Editas Medicine.
  • Collaborations with immuno-oncology firms to develop CAR-T and TCR therapies.

3. Clinical and Commercial Services

MaxCyte provides a range of services to support its partners’ clinical and commercial activities. These services include process development, regulatory support, and manufacturing assistance. By offering end-to-end solutions, MaxCyte ensures the success of its partners’ therapeutic programs.

Business Model

MaxCyte operates a hybrid business model that combines product sales, licensing agreements, and service offerings. The company generates revenue through the sale of its ExPERT™ instruments and consumables, as well as through licensing fees, milestone payments, and royalties from its partners. This diversified revenue stream provides financial stability and supports ongoing innovation.

MaxCyte’s approach to business is highly collaborative. By partnering with leading pharmaceutical and biotechnology companies, the company leverages its technology to accelerate the development of cell-based therapies. This collaborative model not only drives revenue but also positions MaxCyte as a key player in the biotechnology ecosystem.

Strategic Direction

MaxCyte is focused on expanding its presence in the rapidly growing cell and gene therapy market. The company’s strategic priorities include:

  • Technology Innovation: Continuing to enhance the capabilities of the Flow Electroporation® platform to meet the evolving needs of the biotechnology industry.
  • Market Expansion: Increasing its footprint in global markets, particularly in Asia and Europe.
  • Sustainability Goals: Implementing environmentally friendly practices in its operations and product development.
  • New Product Categories: Exploring opportunities in emerging areas such as in vivo gene editing and RNA-based therapies.

Competitive Landscape

MaxCyte operates in a highly competitive market, with several companies offering cell engineering technologies and services. Key competitors include:

  • Lonza Group: A leading provider of cell and gene therapy manufacturing solutions.
  • Thermo Fisher Scientific: Offers a range of cell engineering tools and reagents.
  • Miltenyi Biotec: Specializes in cell separation and engineering technologies.
  • Sangamo Therapeutics: Focuses on gene editing and cell therapy development.

Despite the competition, MaxCyte differentiates itself through its proprietary Flow Electroporation® technology, which offers superior performance and scalability.

Risk Factors

MaxCyte faces several risks that could impact its business:

  • Market Dependence: The company’s success is closely tied to the adoption of cell-based therapies, which are still in the early stages of commercialization.
  • Regulatory Challenges: The development and approval of cell-based therapies are subject to stringent regulatory requirements, which could delay or hinder progress.
  • Supply Chain Disruptions: Dependence on specialized materials and components makes the company vulnerable to supply chain issues.
  • Competition: The biotechnology sector is highly competitive, with new entrants and technologies posing a constant threat.

Recent Developments

MaxCyte has made significant strides in recent years, including:

  • Product Launches: Introduction of new ExPERT™ instruments and consumables to enhance cell engineering capabilities.
  • Partnerships: Expansion of its collaboration network, including new agreements with leading gene editing and immuno-oncology companies.
  • Corporate Strategies: Strengthening its intellectual property portfolio and investing in research and development to maintain its competitive edge.
  • Global Developments: The COVID-19 pandemic highlighted the importance of cell-based therapies, driving increased interest in MaxCyte’s technology.

Investment Considerations

Strengths:

  • Proprietary technology with broad applications in cell and gene therapy.
  • Strong partnerships with leading pharmaceutical and biotechnology companies.
  • Diversified revenue streams from product sales, licensing, and services.
  • Robust intellectual property portfolio.

Risks:

  • Dependence on the success of cell-based therapies.
  • Exposure to regulatory and competitive pressures.
  • Potential supply chain disruptions.

Conclusion

MaxCyte, Inc. is a leader in the biotechnology sector, with a strong focus on cell engineering and therapeutic development. The company’s proprietary Flow Electroporation® technology has positioned it as a key enabler of next-generation therapies. With a robust business model, strategic partnerships, and a commitment to innovation, MaxCyte is well-positioned for future growth. However, investors should carefully consider the risks associated with the biotechnology sector before making investment decisions.